As published previously here, and in our quarterly newsletters, the inclusion of CUP within the 100K Genome Project has been a cause of concern. We greeted the initial inclusion of CUP as a priority by the Chief Medical Office with enthusiasm. This was tempered by the subsequent decision of the newly formed Genomics England not to include CUP initially. In a discussion (22 Apr) between the Director and Prof Mark Caulfield, GeL’s chief scientist, it would seem that CUP has a high likelihood of being included on the main programme. Prof Caulfield’s  priorities with regard to the selection of cancer types is based on ‘where there is scientific potential to make inroads’ and he is keen to ‘include the more challenging cancers’ and to ‘meet unmet needs’. There are many practical aspects that have yet to be addressed but we will continue to engage with GeL and promote the benefits to all cancer patients with advanced metastatic cancers of understanding the ‘driver mutations’ of CUP.

< Back to articles